FDA
-
-
-
-
-
-
-
Upstream Bio (UPB) PT Lowered to $50 at Mizuho
-
-
-
-
-
-
-
Upstream Bio to present Phase 2 trial data at AAAAI meeting
-
-
-
-
-
-
-
Upstream Bio presents verekitug mechanism data at respiratory conference
-
-
-
-
-
-
-
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
-
-
-
-
-
-
-
Upstream Bio Announces Addition to Russell 2000® Index
-
328,194 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

